Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high-risk acute myeloid leukaemia ineligible for intensive chemotherapy. (2022)

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1111/bjh.17823

PubMed Identifier: 34490623

Publication URI: http://europepmc.org/abstract/MED/34490623

Type: Journal Article/Review

Volume: 196

Parent Publication: British journal of haematology

Issue: 2

ISSN: 0007-1048